Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 232946, 16 pages
http://dx.doi.org/10.1155/2014/232946
Review Article

Targeting FASN in Breast Cancer and the Discovery of Promising Inhibitors from Natural Products Derived from Traditional Chinese Medicine

School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong

Received 17 September 2013; Revised 27 December 2013; Accepted 15 January 2014; Published 13 March 2014

Academic Editor: Min Li

Copyright © 2014 Chien-shan Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Boyle and B. Levin, World Cancer Report, IARC Press, Lyon, France, 2008.
  3. R. Alteri, C. Barnes, A. Burke et al., American Cancer Society. Breast Cancer Facts & Figures 2013-2014, American Cancer Society, 2013.
  4. A. R. Carmichael and T. Bates, “Obesity and breast cancer: a review of the literature,” Breast, vol. 13, no. 2, pp. 85–92, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. H. D. Nelson, B. Zakher, A. Cantor et al., “Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis,” Annals of Internal Medicine, vol. 156, no. 9, pp. 635–648, 2012. View at Google Scholar · View at Scopus
  6. A. Montazeri, J. Sadighi, F. Farzadi et al., “Weight, height, body mass index and risk of breast cancer in postmenopausal women: a case-control study,” BMC Cancer, vol. 8, article 278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. Agilent Technologies Affymetrix, Applied Biosystems, AstraZeneca, Novartis Oncology, Pfizer, and Roche Diagnostics, “The Third International Symposium on the Molecular Biology of Breast Cancer,” Breast Cancer Research, vol. 7, supplement 2, pp. S1–S62, 2005. View at Google Scholar
  8. E. Ernst, “Complementary and alternative medicine (CAM) and cancer: the kind face of complementary medicine,” International Journal of Surgery, vol. 7, no. 6, pp. 499–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. W. L. W. Hsiao and L. Liu, “The role of traditional Chinese herbal medicines in cancer therapy from TCM theory to mechanistic insights,” Planta Medica, vol. 76, no. 11, pp. 1118–1131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-J. Li, J.-P. Fu, and J. T. Li, “Chinese medicine approach in clinical practice for breast cancer survivors,” Chinese Journal of Integrative Medicine, vol. 4, pp. 308–315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-Y. Pan, S.-B. Chen, H.-G. Dong et al., “New perspectives on chinese herbal medicine (Zhong-Yao) research and development,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 403709, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Wang, S. Penchala, S. Prabhu, J. Wang, and Y. Huang, “Molecular basis of traditional chinese medicine in cancer chemoprevention,” Current Drug Discovery Technologies, vol. 7, no. 1, pp. 67–75, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Newman, G. M. Cragg, and K. M. Snader, “Natural products as sources of new drugs over the period 1981–2002,” Journal of Natural Products, vol. 66, no. 7, pp. 1022–1037, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Miller, J. Stagl, D. B. Wallerstedt, M. Ryan, and P. J. Mansky, “Botanicals used in complementary and alternative medicine treatment of cancer: clinical science and future perspectives,” Expert Opinion on Investigational Drugs, vol. 17, no. 9, pp. 1353–1364, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Wang, N. Wang, J. Chen, and J. Shen, “Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 873175, 13 pages, 2012. View at Publisher · View at Google Scholar
  16. X. F. Zhai, Z. Chen, B. Li et al., “Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial,” Journal of Integrative Medicine, vol. 11, pp. 90–100, 2013. View at Publisher · View at Google Scholar
  17. M. J. Khandekar, P. Cohen, and B. M. Spiegelman, “Molecular mechanisms of cancer development in obesity,” Nature Reviews Cancer, vol. 11, no. 12, pp. 886–895, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Shi and P. Burn, “Lipid metabolic enzymes: emerging drug targets for the treatment of obesity,” Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 695–710, 2004. View at Google Scholar · View at Scopus
  19. R. Ballard-Barbash, S. Hunsberger, M. H. Alciati et al., “Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations,” Journal of the National Cancer Institute, vol. 101, no. 9, pp. 630–643, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. E. Zagami, N. Golmakani, F. H. Shandiz, and A. Saki, “Evaluating the relationship between body size and body shape with the risk of breast cancer,” Oman Medical Journal, vol. 28, pp. 389–394, 2013. View at Publisher · View at Google Scholar
  21. X. L. Wang, C. X. Jia, L. Y. Liu, Q. Zhang, Y. Y. Li, and L. Li, “Obesity, diabetes mellitus, and the risk of female breast cancer in Eastern China,” World Journal of Surgical Oncology, vol. 11, article 71, 2013. View at Publisher · View at Google Scholar
  22. L. Garrido-Sánchez, J. Vendrell, D. Fernández-García et al., “De novo lipogenesis in adipose tissue is associated with course of morbid obesity after bariatric surgery,” PLoS ONE, vol. 7, no. 2, Article ID e31280, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Lupu and J. A. Menendez, “Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators?” Endocrinology, vol. 147, no. 9, pp. 4056–4066, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. S. Strable and J. M. Ntambi, “Genetic control of de novo lipogenesis: role in diet-induced obesity,” Critical Reviews in Biochemistry and Molecular Biology, vol. 45, no. 3, pp. 199–214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Mashima, H. Seimiya, and T. Tsuruo, “De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy,” British Journal of Cancer, vol. 100, no. 9, pp. 1369–1372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. Q. Chen and Y. Zhang, “Effect of functional factors in the hull of camellia oleifera abel. On obesity and dyslipidemia,” China Academic Journal, 2011. View at Google Scholar
  27. B. P. Atshaves, G. G. Martin, H. A. Hostetler, A. L. McIntosh, A. B. Kier, and F. Schroeder, “Liver fatty acid-binding protein and obesity,” Journal of Nutritional Biochemistry, vol. 21, no. 11, pp. 1015–1032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Suba, “Circulatory estrogen level protects against breast cancer in obese women,” Recent Patents on Anti-Cancer Drug Discovery, vol. 8, pp. 154–167, 2013. View at Google Scholar
  29. J. S. Varghese, D. J. Thompson, K. Michailidou et al., “Mammographic breast density and breast cancer: evidence of a shared genetic basis,” Cancer Research, vol. 72, no. 6, pp. 1478–1484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. E. S. Pizer, J. Thupari, W. F. Han et al., “Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts,” Cancer Research, vol. 60, no. 2, pp. 213–218, 2000. View at Google Scholar · View at Scopus
  31. W. Zhou, Y. Tu, P. J. Simpson, and F. P. Kuhajda, “Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells,” Oncogene, vol. 28, no. 33, pp. 2979–2987, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Zhao, D. Feng, Q. Wang et al., “Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1,” Journal of Clinical Investigation, vol. 122, pp. 2417–2427, 2012. View at Publisher · View at Google Scholar
  33. F. J. Asturias, J. Z. Chadick, I. K. Cheung et al., “Structure and molecular organization of mammalian fatty acid synthase,” Nature Structural and Molecular Biology, vol. 12, no. 3, pp. 225–232, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Jayakumar, M.-H. Tai, W.-Y. Huang et al., “Human fatty acid synthase: properties and molecular cloning,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 19, pp. 8695–8699, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. F. P. Kuhajda, “Fatty acid synthase and cancer: new application of an old pathway,” Cancer Research, vol. 66, no. 12, pp. 5977–5980, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. F. P. Kuhajda, E. S. Pizer, J. N. Li, N. S. Mani, G. L. Frehywot, and C. A. Townsend, “Synthesis and antitumor activity of an inhibitor of fatty acid synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3450–3454, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. S. S. Chirala and S. J. Wakil, “Structure and function of animal fatty acid synthase,” Lipids, vol. 39, no. 11, pp. 1045–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. W. Clendening and L. Z. Penn, “Targeting tumor cell metabolism with statins,” Oncogene, vol. 31, pp. 4967–4978, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. R. J. DeBerardinis, “Is cancer a disease of abnormal cellular metabolism? New angles on an old idea,” Genetics in Medicine, vol. 10, no. 11, pp. 767–777, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. E. S. Pizer, F. D. Wood, H. S. Heine, F. E. Romantsev, G. R. Pasternack, and F. P. Kuhajda, “Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer,” Cancer Research, vol. 56, no. 6, pp. 1189–1193, 1996. View at Google Scholar · View at Scopus
  41. Q. Fu, W. Cai, M. Wang, and Y. Wang, “Effects of inhibiting fatty acid synthase on the growth of colorectal cancer cells and its mechanism,” Chinese Journal of Gastroenterology, vol. 7, no. 4, pp. 202–205, 2002. View at Google Scholar · View at Scopus
  42. J. A. Menendez and R. Lupu, “Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis,” Nature Reviews Cancer, vol. 7, no. 10, pp. 763–777, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Georgiadi and S. Kersten, “Mechanisms of gene regulation by fatty acids,” Advances in Nutrition, vol. 3, pp. 127–134, 2012. View at Publisher · View at Google Scholar
  44. I. Kelesidis, T. Kelesidis, and C. S. Mantzoros, “Adiponectin and cancer: a systematic review,” British Journal of Cancer, vol. 94, no. 9, pp. 1221–1225, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. F. P. Kuhajda, “AMP-activated protein kinase and human cancer: cancer metabolism revisited,” International Journal of Obesity, vol. 32, no. 4, pp. S36–S41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. J. A. Menendez, L. Vellon, and R. Lupu, “Antitumoral actions of the anti-obesity drug orlistat (Xenical) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene,” Annals of Oncology, vol. 16, no. 8, pp. 1253–1267, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. S. S. Chirala, A. Jayakumar, Z.-W. Gu, and S. J. Wakil, “Human fatty acid synthase: role of interdomain in the formation of catalytically active synthase dimer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 6, pp. 3104–3108, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. H.-Y. Chuang, Y.-F. Chang, and J.-J. Hwang, “Antitumor effect of orlistat, a fatty acid synthase inhibitor, is via activation of caspase-3 on human colorectal carcinoma-bearing animal,” Biomedicine and Pharmacotherapy, vol. 65, no. 4, pp. 286–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Flavin, S. Peluso, P. L. Nguyen, and M. Loda, “Fatty acid synthase as a potential therapeutic target in cancer,” Future Oncology, vol. 6, no. 4, pp. 551–562, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. S. K. Kachhap, P. P. Dange, R. H. Santani, S. S. Sawant, and S. N. Ghosh, “Effect of ω-3 fatty acid (docosahexanoic acid) on BRCA1 gene expression and growth in MCF-7 cell line,” Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 3, pp. 257–263, 2001. View at Google Scholar · View at Scopus
  51. M. Wu, K. A. Harvey, N. Ruzmetov et al., “Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway,” International Journal of Cancer, vol. 117, no. 3, pp. 340–348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Vazquez-Martin, S. Ropero, J. Brunet, R. Colomer, and J. A. Menendez, “Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells,” Oncology reports, vol. 18, no. 4, pp. 973–980, 2007. View at Google Scholar · View at Scopus
  53. E. S. Pizer, F. J. Chrest, J. A. DiGiuseppe, and W. F. Han, “Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines,” Cancer Research, vol. 58, no. 20, pp. 4611–4615, 1998. View at Google Scholar · View at Scopus
  54. G. Gago, L. Diacovich, A. Arabolaza, S.-C. Tsai, and H. Gramajo, “Fatty acid biosynthesis in actinomycetes,” FEMS Microbiology Reviews, vol. 35, no. 3, pp. 475–497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Vazquez-Martin, R. Colomer, J. Brunet, and J. A. Menendez, “Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting “HER2 super-expression” occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells,” International Journal of Oncology, vol. 31, no. 4, pp. 769–776, 2007. View at Google Scholar · View at Scopus
  56. S. Lu, G. Yu, Y. Zhu, and M. C. Archer, “Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation,” International Journal of Cancer, vol. 116, no. 6, pp. 847–852, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Zhou, P. J. Simpson, J. M. McFadden et al., “Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells,” Cancer Research, vol. 63, no. 21, pp. 7330–7337, 2003. View at Google Scholar · View at Scopus
  58. V. Fritz and L. Fajas, “Metabolism and proliferation share common regulatory pathways in cancer cells,” Oncogene, vol. 29, no. 31, pp. 4369–4377, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. S. M. Hadad, D. G. Hardie, V. Appleyard, and A. M. Thompson, “Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle,” Clinical and Translational Oncology, 2013. View at Publisher · View at Google Scholar
  60. Z.-Y. Wang, D.-M. Wang, T. Y. Loo et al., “Spatholobus suberectus inhibits cancer cell growth by inducing apoptosis and arresting cell cycle at G2/M checkpoint,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 751–758, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Y. Wang, F. P. Kuhajda, J. Li et al., “Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer,” Journal of Experimental Therapeutics and Oncology, vol. 4, no. 2, pp. 101–110, 2004. View at Google Scholar · View at Scopus
  62. J. S. Lee, J. Y. Sul, J. B. Park et al., “Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells,” Phytotherapy Research, vol. 27, pp. 713–720, 2013. View at Publisher · View at Google Scholar
  63. J. A. Menendez, I. Mehmi, V. A. Verma, P. K. Teng, and R. Lupu, “Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation,” Molecular Carcinogenesis, vol. 41, no. 3, pp. 164–178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. P. D. Schley, H. B. Jijon, L. E. Robinson, and C. J. Field, “Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells,” Breast Cancer Research and Treatment, vol. 92, no. 2, pp. 187–195, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. W.-X. Tian, R.-F. Jiang, H.-B. Wu, Y.-H. Shi, and Y.-H. Wang, “The substrate inhibition by NADPH and kinetics of fatty acid synthase from duck liver,” Chinese Biochemical Journal, vol. 10, no. 4, pp. 413–419, 1994. View at Google Scholar
  66. T. Maier, S. Jenni, and N. Ban, “Architecture of mammalian fatty acid synthase at 4.5 å resolution,” Science, vol. 311, no. 5765, pp. 1258–1262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. J. A. Menendez, R. Colomer, and R. Lupu, “Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?” Medical Hypotheses, vol. 64, no. 2, pp. 342–349, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. L. Eissing, T. Scherer, K. Todter et al., “De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health,” Nature Communications, vol. 4, p. 1528, 2013. View at Publisher · View at Google Scholar
  69. A. Rinke, H.-H. Müller, C. Schade-Brittinger et al., “Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4656–4663, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. A. T. Willingham, Q. L. Deveraux, G. M. Hampton, and P. Aza-Blanc, “RNAi and HTS: exploring cancer by systematic loss-of-function,” Oncogene, vol. 23, no. 51, pp. 8392–8400, 2004. View at Publisher · View at Google Scholar · View at Scopus
  71. R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. D. A. Tennant, R. V. Durán, and E. Gottlieb, “Targeting metabolic transformation for cancer therapy,” Nature Reviews Cancer, vol. 10, no. 4, pp. 267–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. I. J. Lodhi, X. Wei, and C. F. Semenkovich, “Lipoexpediency: De novo lipogenesis as a metabolic signal transmitter,” Trends in Endocrinology and Metabolism, vol. 22, no. 1, pp. 1–8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Podo, “Tumour phospholipid metabolism,” NMR in Biomedicine, vol. 12, pp. 413–439, 1999. View at Google Scholar
  76. M. Hilvo, S. Gade, T. Hyotylainen et al., “Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients,” International Journal of Cancer, vol. 134, no. 4, pp. 1725–1733, 2013. View at Publisher · View at Google Scholar
  77. T. Puig, A. Vázquez-Martín, J. Relat et al., “Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75,” Breast Cancer Research and Treatment, vol. 109, no. 3, pp. 471–479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. J. S. Lee, M. S. Lee, W. K. Oh, and J. Y. Sul, “Fatty acid synthase inhibition by amentoflavone induces apoptosis and antiproliferation in human breast cancer cells,” Biological and Pharmaceutical Bulletin, vol. 32, no. 8, pp. 1427–1432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. F. P. Kuhajda, K. Jenner, F. D. Wood et al., “Fatty acid synthesis: a potential selective target for antineoplastic therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 14, pp. 6379–6383, 1994. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Kawaguchi, H. Tomoda, S. Nozoe, S. Omura, and S. Okuda, “Mechanism of action of cerulenin on fatty acid synthetase: effect of cerulenin on iodoacetamide-induced malonyl-coa decarboxylase activity,” Journal of Biochemistry, vol. 92, no. 1, pp. 7–12, 1982. View at Google Scholar · View at Scopus
  81. F. P. Kuhajda, “Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology,” Nutrition, vol. 16, no. 3, pp. 202–208, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. J. N. Thupari, M. L. Pinn, and F. P. Kuhajda, “Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity,” Biochemical and Biophysical Research Communications, vol. 285, no. 2, pp. 217–223, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. X. Wang and W. Tian, “Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase,” Biochemical and Biophysical Research Communications, vol. 288, no. 5, pp. 1200–1206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. W. P. Xiao, R. Zhang, and Y. H. Sun, “Enhancement of inhibitory activity of green tea extract on fatty acid synthase by hydrogen ion,” Chinese Journal of Biochemistry and Molecular Biology, vol. 22, pp. 234–238, 2006. View at Google Scholar
  85. Z. Rui, X. Wen-Ping, and T. Wei-Xi, “Inhibitory effects of green tea extract on fatty acid synthase,” Journal of Yunnan University, vol. 26, pp. 42–47, 2004. View at Google Scholar
  86. M.-H. Pan, C.-C. Lin, J.-K. Lin, and W.-J. Chen, “Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-β1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling,” Journal of Agricultural and Food Chemistry, vol. 55, no. 13, pp. 5030–5037, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Puig Miquel, J. Relat, P. F. Marrero, D. Haro, J. Brunet, and R. Colomer, “Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals,” Anticancer Research, vol. 28, no. 6, pp. 3671–3676, 2008. View at Google Scholar · View at Scopus
  88. M. J. Vázquez, W. Leavens, R. Liu et al., “Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β-ketoacyl reductase reaction,” FEBS Journal, vol. 275, no. 7, pp. 1556–1567, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. T. M. Loftus, D. E. Jaworsky, C. L. Frehywot et al., “Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors,” Science, vol. 288, no. 5475, pp. 2379–2381, 2000. View at Publisher · View at Google Scholar · View at Scopus
  90. J. N. Thupari, L. E. Landree, G. V. Ronnett, and F. P. Kuhajda, “C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 14, pp. 9498–9502, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Zhang, “Induction of cancer cell apoptosis and growth inhibition by icaritin is associated with its ability to suppress fatty acid synthase activity,” China Academic Journal, 2009. View at Google Scholar
  92. G. K. Dae, H. Y. Ming, H. Oh, H. L. Dae, and S. L. Ho, “Vasorelaxation by amentoflavone isolated from Selaginella tamariscina,” Planta Medica, vol. 70, no. 8, pp. 718–722, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. Y.-M. Lin, H. Anderson, M. T. Flavin et al., “In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora,” Journal of Natural Products, vol. 60, no. 9, pp. 884–888, 1997. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Mora, M. Paya, J. L. Rios, and M. J. Alcaraz, “Structure-activity relationships of polymethoxyflavones and other flavonoids as inhibitors of non-enzymic lipid peroxidation,” Biochemical Pharmacology, vol. 40, no. 4, pp. 793–797, 1990. View at Publisher · View at Google Scholar · View at Scopus
  95. W.-Y. Wu and Q.-G. Yu, “Grape seed extract in the fatty acid synthase inhibitors, chemical composition and activity determination,” Chinese Academic Journal, vol. 6, 2008. View at Google Scholar
  96. F. Yu, J. Gao, Y. Zeng, and C.-X. Liu, “Inhibition of Coix seed extract on fatty acid synthase, a novel target for anticancer activity,” Journal of Ethnopharmacology, vol. 119, no. 2, pp. 252–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. W.-A. Ding, M. Du, and Y. Chen, “Study of coix seed chemical composition and its mechanism of tumor and its prevention,” Jilin Journal of Traditional Chinese Medicine, vol. 12, 2012. View at Google Scholar
  98. L. Y. Wang, F. Le, N. Wang et al., “Alteration of fatty acid metabolism in the liver, adipose tissue, and testis of male mice conceived through assisted reproductive technologies: fatty acid metabolism in ART mice,” Lipids in Health and Disease, vol. 12, article 5, 2013. View at Publisher · View at Google Scholar
  99. Y. J. Choi, Y. Yoon, H. S. Choi et al., “Effects of medicinal herb extracts and their components on steatogenic hepatotoxicity in Sk-Hep1 cells,” Toxicology Research, vol. 27, pp. 211–216, 2011. View at Publisher · View at Google Scholar
  100. B. Challier, J.-M. Perarnau, and J.-F. Viel, “Garlic, onion and cereal fibre as protective factors for breast cancer: a French case-control study,” European Journal of Epidemiology, vol. 14, no. 8, pp. 737–747, 1998. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Sengupta, S. Ghosh, and S. Bhattacharjee, “Allium vegetables in cancer prevention: an overview,” Asian Pacific Journal of Cancer Prevention, vol. 5, no. 3, pp. 237–245, 2004. View at Google Scholar · View at Scopus
  102. Y. Wang, W. X. Tian, and X. F. Ma, “Inhibitory effects of onion (Allium cepa L.) extract on proliferation of cancer cells and adipocytes via inhibiting fatty acid synthase,” Asian Pacific Journal of Cancer Prevention, vol. 13, pp. 5573–5579, 2012. View at Publisher · View at Google Scholar
  103. C. Y. Ragasa, R. D. De Luna, W. C. Cruz Jr., and J. A. Rideout, “Monoterpene lactones from the seeds of Nephelium lappaceum,” Journal of Natural Products, vol. 68, no. 9, pp. 1394–1396, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. Y.-X. Zhao, W.-J. Liang, H.-J. Fan et al., “Fatty acid synthase inhibitors from the hulls of Nephelium lappaceum L,” Carbohydrate Research, vol. 346, no. 11, pp. 1302–1306, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. W.-X. Tian, L.-C. Li, X.-D. Wu, and C.-C. Chen, “Weight reduction by Chinese medicinal herbs may be related to inhibition of fatty acid synthase,” Life Sciences, vol. 74, no. 19, pp. 2389–2399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. J.-B. Sun, X.-G. Lu, and J.-S. Tang, “The effect of compound recipe TFR combined with exercise on the activity of FAS to diet-induced hypercholesteremia rats,” Journal of Huaiyin Teachers College, vol. 7, pp. 64–68, 2008. View at Google Scholar
  107. Y. Y. Zhang, F. Z. Zhang, L. Y. Sun, and X. Z. Wang, “Inhibition to fatty acid synthase from human breast cancer cell with extract of Tuber Fleeceflower root in vitro,” Journal of Qiqihar Medical College, vol. 25, pp. 1102–1104, 2004. View at Google Scholar
  108. W.-X. Tian, “Inhibition of fatty acid synthase by polyphenols,” Current Medicinal Chemistry, vol. 13, no. 8, pp. 967–977, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. X. F. Ma, Y. Liu, and S. G. Zhang, “Relationship between pharmic character of warm/cold traditional Chinese medicines and their inhibition to fatty acid synthase,” Journal of Graduate University of Chinese Academy of Sciences, vol. 29, pp. 699–706, 2012. View at Google Scholar
  110. H. Y. Song, L. Zhang, J. L. Pan, L. L. Yang, and G. Ji, “Bioactivity of five components of Chinese herbal formula Jiangzhi granules against hepatocellular steatosis,” Journal of Integrative Medicine, vol. 11, pp. 262–268, 2013. View at Publisher · View at Google Scholar
  111. H. S. Parekh, G. Liu, and M. Q. Wei, “A new dawn for the use of traditional Chinese medicine in cancer therapy,” Molecular Cancer, vol. 8, article 21, 2009. View at Publisher · View at Google Scholar · View at Scopus